Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012818 | Signs and Symptoms, Respiratory NIH | 0.50 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The main objective of the ANACONDA-COVID-19 trial is to assess the efficacy of Anakinra + optimized Standard of Care (oSOC) as compared to oSOC alone on the condition of patients with COVID-19 infection and worsening respiratory symptoms. Success defined as patient alive and free of invasive mechanical ventilation (IMV) and free of Extracorporeal Membrane Oxygenation (ECMO) at Day 14.
Description: The primary endpoint is treatment success at Day 14, defined as a patient alive and not requiring any of the following: Invasive mechanical ventilation (IMV) or Extracorporeal membrane oxygenation (ECMO).
Measure: Treatment success Time: After 14 days of treatmentDescription: Defined as a patient alive and not requiring any of the following: Invasive mechanical ventilation (IMV) or Extracorporeal membrane oxygenation (ECMO).
Measure: Treatment success Time: After 3 days, 10 days and 28 days of treatmentDescription: 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;6. Hospitalized, on invasive mechanical ventilation or ECMO;7. Death.
Measure: OMS progression scale (on a 7 point ordinal scale) Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: Overall survival
Measure: Overall survival Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: Time to ICU admission
Measure: Time to ICU admission Time: Up to 28 daysDescription: Time to ventilatory support : extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, non-invasive ventilation, high flow oxygen therapy)
Measure: Time to ventilatory support Time: Up to 28 daysDescription: The National Early Warning Score (NEWS) determines the degree of illness of a patient using six physiological findings and one observation. Score from 0 to 20, 0 mean a worse outcome, 20 mean a better outcome
Measure: Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28 Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: C-reactive proteine (mg/L)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: ferritin (ng/mL)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: lymphocyte count (G/L)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: fibrinogen (g/l)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: Hospital length of stay
Measure: Hospital length of stay Time: Up to 28 daysDescription: Need for Vasopressors (yes or no)
Measure: ICU parameter Time: Up to 28 daysDescription: Evolution of SpO2/FIO2 ratio (no unit)
Measure: ICU parameter Time: Up to 28 daysDescription: Evolution of PaO2/FiO2 ratio (no unit)
Measure: ICU parameter Time: Up to 28 daysDescription: Occurrence of serious adverse events during the study, including infection (bacterial, parasitic, mycotic and viral infection), septic shock, Ankanira hypersensitivity, hepatic damages (SGOT/SGPT, alkaline phosphatase, gammaGT) and neutropenia (Blood count).
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: Up to 28 daysDescription: The correlation between several of clinical parameters at inclusion (including level of oxygen requirement (saturation), respiratory rate (per min), temperature (°C)…), biological parameters :including, CRP (mg/L), ferritin (µg/L), LDH (UI/L), lymphocyte count (G/L), eosinophil count (G/L), Ddimers (ng/mM), platelet count (G/L), polymorphonuclear count (G/L)...with the primary end point will be explored.
Measure: Predictors of efficacy of Anakinra Time: After 14 days of treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports